

What Clinicians Want to Know: Optimizing the Management of Metastatic Triple-Negative Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. What was the primary objective of the Phase II PRIMED study of sacituzumab govitecan for advanced breast cancer?**
 - To evaluate the efficacy and safety of sacituzumab govitecan for previously untreated PD-L1-negative metastatic triple-negative breast cancer (mTNBC)
 - To evaluate prophylactic granulocyte colony-stimulating factor and loperamide in improving the tolerability of sacituzumab govitecan
 - To evaluate the effectiveness of various dose levels and schedules of sacituzumab govitecan in improving tolerability
- 2. Data from the Phase III TROPION-Breast02 study suggest that datopotamab deruxtecan (Dato-DXd) as a component of first-line therapy improves overall survival and progression-free survival (PFS) for patients with mTNBC in which of the following settings?**
 - In combination with durvalumab for patients with PD-L1-positive disease
 - As monotherapy for patients for whom immunotherapy is not an option
 - Both a and b
 - None of the above
- 3. The Phase III ASCENT-03 study evaluating first-line sacituzumab govitecan versus chemotherapy for patients with mTNBC who are not candidates for PD-1/PD-L1 inhibitors reported which of the following outcomes?**
 - Inferior PFS with sacituzumab govitecan
 - Numerical but nonsignificant improvement in PFS with sacituzumab govitecan
 - Statistically significant improvement in PFS with sacituzumab govitecan
- 4. Which of the following outcomes was reported for patients who received first-line sacituzumab govitecan with pembrolizumab in comparison to chemotherapy with pembrolizumab for PD-L1-positive mTNBC in the Phase III ASCENT-04/KEYNOTE-D19 trial?**
 - Higher objective response rate
 - Significant PFS benefit
 - Both a and b
- 5. For a patient who experiences Grade 3 oral mucositis/stomatitis while receiving Dato-DXd and is receiving prophylactic medications, what is the recommended next step?**
 - Continue Dato-DXd uninterrupted
 - Hold Dato-DXd until oral mucositis/stomatitis resolves to Grade ≤ 1 , then resume at the same dose level
 - Hold Dato-DXd until oral mucositis/stomatitis resolves to Grade ≤ 1 , then resume at a reduced dose level
 - Permanently discontinue Dato-DXd